Acrivon Therapeutics, Inc. (ACRV) Stock Statistics & Valuation Metrics

Acrivon Therapeutics, Inc. has a market cap or net worth of $60.05M. The enterprise value is $10.12M.

Acrivon Therapeutics, Inc. has 38,744,446 shares outstanding. The number of shares has decreased by -2.65% in one year.

Acrivon Therapeutics, Inc.’s return on equity (ROE) is -0.69 and return on invested capital (ROIC) is -73.00%.

The current PE Ratio of Acrivon Therapeutics, Inc. is ―. Acrivon Therapeutics, Inc.’s PEG ratio is 0.31.

In the last 12 months, Acrivon Therapeutics, Inc. had revenue of 0.00 and earned -77.91M in profits. Earnings per share was -2.02.

In the last 12 months, operating cash flow was -63.66M and capital expenditures -1.67M, giving a free cash flow of -65.33M billion.

Acrivon Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Acrivon Therapeutics, Inc. upcoming earnings date is May 20, 2026, Before Open (Confirmed).

Acrivon Therapeutics, Inc. as a current ratio of 7.69, with Debt / Equity ratio of 2.41%

In the past 12 months, Acrivon Therapeutics, Inc. has paid 0.00 in taxes.

Acrivon Therapeutics, Inc. EV to EBITDA ratio is -0.65, with an EV/FCF ratio of -0.83.

Acrivon Therapeutics, Inc. has $118.58M in cash and marketable securities with $2.71M in debt, giving a net cash position of $115.87M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Acrivon Therapeutics, Inc. is $13.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy